| Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody (NCT02159443) | St. Jude Children's Research Hospital | 2014-07-15 |
| 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat (NCT02035137) | New Approaches to Neuroblastoma Therapy Consortium | 2014-07-01 |
| GA-68 DOTA-TOC of Somatostatin Positive Malignancies (NCT02177773) | University of California, San Francisco | 2014-06-23 |
| Phase II Study of Proton Radiation Therapy for Neuroblastoma (NCT02112617) | Massachusetts General Hospital | 2014-06-01 |
| iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (NCT01953900) | Baylor College of Medicine | 2014-04-01 |
| MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors (NCT02076906) | AeRang Kim | 2014-04-01 |
| A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (NCT01288573) | Genzyme, a Sanofi Company | 2014-03-03 |
| Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma (NCT02100930) | Memorial Sloan Kettering Cancer Center | 2014-03-01 |
| A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors (NCT02107963) | National Cancer Institute (NCI) | 2014-02-28 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors (NCT01962103) | Celgene | 2013-12-04 |
| Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors (NCT02013336) | South Plains Oncology Consortium | 2013-12-01 |
| Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer (NCT01987596) | Barbara Ann Karmanos Cancer Institute | 2013-08-01 |
| 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN (NCT01822652) | Baylor College of Medicine | 2013-08-01 |
| A Pilot Study on ALK Gene Mutations in Neuroblastoma (NCT01986595) | National Taiwan University Hospital | 2013-08-01 |
| Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma (NCT01916187) | NCIC Clinical Trials Group | 2013-07-30 |
| Therapy for Children With Advanced Stage Neuroblastoma (NCT01857934) | St. Jude Children's Research Hospital | 2013-07-05 |
| Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children (NCT02308527) | University of Birmingham | 2013-07-01 |
| NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors (NCT01875601) | National Cancer Institute (NCI) | 2013-06-11 |
| Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma (NCT01747876) | Novartis Pharmaceuticals | 2013-05-28 |
| Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors (NCT01807468) | Samsung Medical Center | 2013-05-01 |
| Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) (NCT01868269) | Institut Curie | 2013-04-18 |
| Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT (NCT01869725) | Sue O'Dorisio | 2013-04-01 |
| Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (NCT02100891) | Monica Thakar | 2013-03-20 |
| A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma (NCT01802138) | Seoul National University Hospital | 2013-02-01 |
| Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma (NCT01757626) | Memorial Sloan Kettering Cancer Center | 2012-12-01 |
| Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma (NCT01460901) | Children's Mercy Hospital Kansas City | 2012-10-01 |
| A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas (NCT01625351) | St. Jude Children's Research Hospital | 2012-08-20 |
| Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors (NCT01662804) | Memorial Sloan Kettering Cancer Center | 2012-08-06 |
| ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma (NCT01592045) | United Therapeutics | 2012-08-01 |
| iCAT for Recurrent/Refractory/HR Solid Tumors (NCT01853345) | Dana-Farber Cancer Institute | 2012-08-01 |
| Study of MLN8237 in Combination With Irinotecan and Temozolomide (NCT01601535) | New Approaches to Neuroblastoma Therapy Consortium | 2012-05-01 |
| Studying Chromosomes in Samples From Younger Patients With Neuroblastoma (NCT01589341) | Children's Oncology Group | 2012-04-01 |
| Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma (NCT01576692) | St. Jude Children's Research Hospital | 2012-04-01 |
| High Dose Chemotherapy and Autologous Transplant for Neuroblastoma (NCT01526603) | Masonic Cancer Center, University of Minnesota | 2012-03-28 |
| Studying Gene Expression in Samples From Younger Patients With Neuroblastoma (NCT01553448) | Children's Oncology Group | 2012-03-01 |
| Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors (NCT01619865) | Sue O'Dorisio | 2012-02-21 |
| Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma (NCT01520233) | Children's Oncology Group | 2012-01-01 |
| Studying Biomarkers in Samples From Patients With High-Risk Neuroblastoma (NCT01510600) | Children's Oncology Group | 2012-01-01 |
| Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors (NCT01518413) | HMeany | 2011-12-01 |
| Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma (NCT01505608) | Giselle Sholler | 2011-12-01 |
| Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma (NCT01492673) | Memorial Sloan Kettering Cancer Center | 2011-12-01 |
| Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma (NCT01483820) | Giselle Sholler | 2011-12-01 |
| Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging (NCT01482741) | Memorial Sloan Kettering Cancer Center | 2011-11-01 |
| Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors (NCT01462396) | Children's Mercy Hospital Kansas City | 2011-10-01 |
| Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors (NCT01419834) | Memorial Sloan Kettering Cancer Center | 2011-08-15 |
| Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma (NCT01404702) | University of Alabama at Birmingham | 2011-08-01 |
| New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma (NCT01174537) | Hadassah Medical Organization | 2011-07-01 |
| Neuroblastoma Biology Study (NCT01587300) | New Approaches to Neuroblastoma Therapy Consortium | 2011-07-01 |
| Protein Expression in Human Neuroblastoma Tumor Samples (NCT01407731) | Children's Oncology Group | 2011-07-01 |
| Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma (NCT01387724) | Children's Oncology Group | 2011-06-01 |
| Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma (NCT01355679) | Giselle Sholler | 2011-05-01 |
| Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer (NCT01353300) | Children's Oncology Group | 2011-05-01 |
| Immunomonitoring of Children With Neuroblastoma (NCT01295762) | Centre Leon Berard | 2011-05-01 |
| Biomarkers in Samples From Young Patients With Neuroblastoma (NCT01358604) | Children's Oncology Group | 2011-05-01 |
| Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors (NCT01331135) | Emory University | 2011-04-01 |
| High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma (NCT01313936) | University of California, San Francisco | 2011-03-01 |
| Aflac ST1001 Prolonged Isotretinoin (NCT01319838) | Emory University | 2011-03-01 |
| Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET) (NCT01308905) | Barbara Ann Karmanos Cancer Institute | 2011-02-01 |
| Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides (NCT01598454) | Laboratorio Elea Phoenix S.A. | 2011-02-01 |
| A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB (NCT01125800) | Novartis Pharmaceuticals | 2011-02-01 |
| To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer (NCT01222780) | Acrotech Biopharma Inc. | 2010-09-01 |
| 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow (NCT01183897) | Memorial Sloan Kettering Cancer Center | 2010-08-12 |
| 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma (NCT01183429) | Memorial Sloan Kettering Cancer Center | 2010-08-12 |
| Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (NCT01241162) | University of Louisville | 2010-08-01 |
| High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation (NCT01183416) | Memorial Sloan Kettering Cancer Center | 2010-08-01 |
| 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma (NCT01183884) | Memorial Sloan Kettering Cancer Center | 2010-08-01 |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients (NCT01169584) | Jennerex Biotherapeutics | 2010-08-01 |
| Biomarkers in Young Patients With Neuroblastoma (NCT01169376) | Children's Oncology Group | 2010-07-01 |
| A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors (NCT01130623) | National Cancer Institute (NCI) | 2010-05-10 |
| A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas (NCT01132911) | National Cancer Institute (NCI) | 2010-05-10 |
| Pharmacokinetic Study of Doxorubicin in Children With Cancer (NCT01095926) | University Hospital Muenster | 2010-05-01 |
| Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma (NCT01114555) | Memorial Sloan Kettering Cancer Center | 2010-04-29 |
| Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies (NCT01109394) | National Cancer Institute (NCI) | 2010-04-21 |
| Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome (NCT00946283) | Rutgers, The State University of New Jersey | 2010-03-01 |
| N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma (NCT01019850) | New Approaches to Neuroblastoma Therapy Consortium | 2010-03-01 |
| HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors (NCT00931931) | Timothy Cripe | 2010-03-01 |
| Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide (NCT01059071) | Giselle Sholler | 2010-02-01 |
| Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant (NCT01077440) | Vanderbilt University | 2010-02-01 |
| Exploring the Possibility to Use Glycosyltransferase as a Prognosis Marker of Neuroblastoma (NCT01638572) | National Taiwan University Hospital | 2010-01-01 |
| Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma (NCT00992173) | Molecular Insight Pharmaceuticals, Inc. | 2010-01-01 |
| N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma (NCT00885326) | New Approaches to Neuroblastoma Therapy Consortium | 2009-12-01 |
| A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) (NCT00960063) | Merck Sharp & Dohme LLC | 2009-11-11 |
| Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma (NCT01204450) | UNC Lineberger Comprehensive Cancer Center | 2009-11-01 |
| Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms (NCT01005654) | National Cancer Institute (NCI) | 2009-10-07 |
| Genomic Structural Variation in Cancer Susceptibility (NCT00996710) | Memorial Sloan Kettering Cancer Center | 2009-10-01 |
| Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features (NCT01048892) | Children's Oncology Group | 2009-09-01 |
| Nurse Case Manager Model on Neuroblastoma Caregiver's Uncertainty (NCT01525251) | National Taiwan University Hospital | 2009-08-01 |
| Methionine PET/CT Studies In Patients With Cancer (NCT00840047) | St. Jude Children's Research Hospital | 2009-07-20 |
| Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours (NCT00918320) | Gustave Roussy, Cancer Campus, Grand Paris | 2009-06-01 |
| A Vaccine Study for High Risk Cancers (NCT00944580) | Penn State University | 2009-06-01 |
| 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) (NCT01048086) | University of Iowa | 2009-06-01 |
| Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma (NCT00911560) | Memorial Sloan Kettering Cancer Center | 2009-05-27 |
| The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells (NCT01868490) | Siriraj Hospital | 2009-04-17 |
| Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma (NCT00877110) | Memorial Sloan Kettering Cancer Center | 2009-04-02 |
| TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma (NCT00867568) | Giselle Sholler | 2009-03-01 |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors (NCT00947167) | Pamela L. Kunz | 2009-03-01 |
| Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA]) (NCT01119560) | Children's Oncology Group | 2009-02-03 |
| Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma (NCT00939965) | Children's Cancer and Leukaemia Group | 2009-02-01 |
| Informed Consent in Pediatric Cancer Trials (NCT00923650) | National Cancer Institute (NCI) | 2008-12-09 |
| Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma (NCT00808899) | St. Jude Children's Research Hospital | 2008-12-01 |